Tuhura Biosciences Unveils Cancer Immunotherapy Advances Targeting Resistance with Three Novel Technologies

Tuhura Biosciences Inc. has released a corporate presentation outlining its progress in developing immuno-oncology therapeutics aimed at overcoming resistance to cancer immunotherapies. The company’s lead asset, IFx-2.0, is currently in a Phase 3 front-line study for Merkel Cell Cancer, with top-line data expected in the first half of 2027. This trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration. Preliminary data from a Phase 1/2 study of IFx-2.0 will be presented at ASCO 2026. Tuhura’s pipeline includes a second asset, TBS-2025, targeting VISTA in NPM1-mutated acute myeloid leukemia (AML), which will enter Phase 2 trials in early 2026, with data anticipated later that year. A third program involving bi-specific antibody-drug conjugates (ADCs) is expected to reach in vivo proof-of-concept in 2026, opening potential partnering opportunities. The company reports a cash position that supports advancement through multiple key milestones. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.